Glaucoma Grand Rounds

Elizabeth D. Muckley, O.D. F.A.A.O. Director of Optometric Services NE Ohio Eye Surgeons Kent -Stow - Akron Emuckley@midwestvision.com

Disclosures

Financial:

- Consultant, Allergan Pharmaceuticals
- Investor, Midwest Vision Partners









Diagnosis

OD: Severe/Advanced Glaucoma OS: Mild Glaucoma (or possibly just OHTN depending on how you interpret OCT and ONH appearance)



Classification of Glaucoma

Proper coding/staging: MILD: ON findings consistent with glaucoma but NO VF abnormalities OR abnormalities present only on SWAP or

FDT MODERATE: ON findings consistent with glaucoma AND glaucomatous VF abnormalities in ONE hemifield and NOT within 5 degrees of fixation

SEVERE: ON abnormalities consistent with glaucoma AND glaucomatous visual field abnormalities in BOTH hemifields AND/OR loss within 5 degrees of fixation in at least one hemifield



IOP GOAL FOR THIS PATIENT

- What would you set as target IOP or range?
- EDM's Target Goal:
 OD <14mm HG
 OS <18mm HG





Setting an IOP Goal

Predicting Rate of Progression

- EMGT
 - Glaucoma progressed slower in the treated group but is variable
 - Every 1 mm Hg matters For every 1 mm Hg reduction in IOP, risk of progression decreases by 10%
 - Follow progression closely and reset target IOP when progression confirmed
 - Pseudoexfoliation glaucoma doubled risk of VF loss

Setting an IOP goal

her Important Considerations

- Age
- Race
- Life expectancy/general health
- Socioeconomic factors
- Living arrangements
- Ability to follow instructions
- Personal hygiene
- Status of other eye



Initiation of Treatment-First-line Options

- Pharmacologic Agent
 - Reach target IOP with fewest meds as possible
 - Reduce aqueous production from ciliary body (beta-blockers, carbonic anhydrase inhibitors, alpha-agonists)
 - Increase outflow via
 Trabecular meshwork (cholinergic, nitric oxide donors, rho kinase inhibitors)
 Uveoscleral pathway (prostaglandins)
- Surgical
 - SLT
- Intracameral Implant

Important to get patient buy in and input on treatment

Treatment for this patient?

- What would you recommend to lower IOP?
- EDM treatment
 - Discussed all options
 - Patient elected meds 1st
 - Started 0.01% Bimatopost qpm (after 5pm but before 10pm)
 - Recommended F/u in 1 month to see IOP reduction

After 1 month

• IOP reduced to • OD: 17mm HG

- OS: 16mm HG
- Are you happy with this?

With amount of damage OD and age of 63, IOP best at 14 or lower Next steps?

- SLT
- 0.5% Timolol in AM OD only

-Change to Latanoprost/Netarsudil combo OU?

Next Steps:

- Patient elected SLT OD
- After 6 weeks post SLT IOP reduced to 12 mm Hg OD
- Recommend F/U in 4 months for IOP check
- VF/OCT testing ?
 - Annually to monitor for progression and establish rate of progression vs. repeating VF in 6 months to establish rate of progression is not fast?

Thoughts/debate on when to re-test?

Monitoring for Progression

- Once glaucoma diagnosis is made, clinician now shifts toward monitoring progression as well as estimating approximate rate of progression
- Functional VF loss negatively affects quality of life (mobility, reading, and driving) and goal as clinician is to reduce or avoid this devasting outcome
 - Rate of progression is individual and may take years to establish or could be rapid
 - Helpful to know if parent or sibling lost vision during their disease course: is this genetically aggressive or slower?

Progression

Important to test VFs and OCTs frequently in early diagnosis to establish reliable baseline and rule out rapid progression

- Rates of MD change in most glaucoma patients vary from 0 to -2.5 dB/year, depending on the severity of disease, treatment, and population samples
- Rapid visual field progression is approximately -1.5 to -2 dB/year
- With intervention, most do not progress at a rate that would lead to functional impairment, but 3–17% of patients will continue to lose vision despite IOP optimum IOP lowering and progress to blindness within 20 years

Chuban BC, Cannay-Neath DF, Carli JJ, et al. Pactical recommendations for measuring rates of visual field change Is automatic BJ (valuational, 2008/Ref)(949-957, doi:10.1106/j.pb.2007.12012.108 Rinnan JF, Huatler A, Bohat H, Toms L, Crabb DP, McHaapht AI, Pertomotith visual Field database: an audit of glascoma progression, Fey. 2004/24(8): 974-974, oci10.1038/sey.2013.234 (10) Sandner JJ, Mederics FA, Weinreb RH, Zangwill LM, What rates of glascoma progression are clinically significant?. Ex-ophrhamin. 2016;11(1):227-234. doi:10.1080/746/9892.2016.1103824

Progression

- Difference of ≥7 µm thinning in superior and inferior quadrants between scans • Difference of ≥4–5 µm thinning for average RNFL difference between scans
- Typical RNFL progression patterns
 - Widening of existing RNFL defect
 - Deepening of current RNFL defect
 - Development of a new RNFL defect Inferior temporal location most common site of progression
- Evaluating progression in advanced glaucoma is best using serial VFs since retinal thinning bottoms out (floor effect)
- Once thinning hits floor, progression can still occur but OCT can't detect it
- Use macular OCT and HVF 10–2 to monitor progression i advanced glaucoma

Guidelines for Testing for Progression

- European Glaucoma Society guidelines: VF testing three times per year in the first 2 years after initial glaucoma diagnosis
- Need to obtain enough VFs initially to get reliability and repeatability
 - Minimum every 12 months if reliable and rate of progression deemed slower

 - Perform 10-2 from time to time to look for macular defects not seen on 24-2

- Evaluate both macular and ON tomography
 ON imaging may not be beneficial for advanced disease due to "floor effect"







| If progression noted on testing | despite maintaining IOP goal |
|--|---|
| Lower IOP further anoth Increase follow up visits a adjust if demonstrates st Consider MIGS interventi significant | rr 3-# points and testing to re-establish rate of progression and ability in VF/OCT/ON testing on earlier and especially if cataracts are visually |
| agnincan | |
| ucation at each visit | |
| ✓ Patients need to understand ✓ Despite our best efforts in I | d we cannot cure or reverse glaucoma OP reduction, progression can still occur |
| ✓ Show patient their VF, OCT, | and disc photos- explain what you are evaluating |
| ✓ Goal is to prevent functional | I decline and decreased quality of life |
| ✓ Re-education on compliance | e and adherence to therapy |



Background 21 year old black, male, Kent State football athlete was hit in the R eye by a snapped exercise band during a work-out earlier today. Pt had pain, swelling of eyelid, and blurred vision Vision 20/200 OD, 20/20 OS. Pupil showed poor reactivity OD,



Fundus

 Poor view of retina due to media, no obvious detachment or commotio, good red reflex

What is our official diagnosis?

How do we treat or manage this patient?

Any special considerations?

Diagnosis Traumatic Hyphema Secondary Acute Glaucom

Hyphema etiology

- Iris sphincter tears are relatively common following blunt ocular trauma
- Vast majority of hyphemas are the result of a tear in the face of the ciliary body
 - Consequent bleeding from the major arterial circle of the iris or other arterial or venous branches supplying the ciliary body
- High risk of angle recession



Angle Recession

- Most individuals developing glaucoma in the setting of ocular trauma with angle recession have at least 180° of angle involvement
- The degree of recession does correlate with the development of glaucoma
- Patients need gonioscopy 4 weeks after trauma



Special Considerations

 Is patient on any other meds that thin blood?

• NSAIDs, Coumadin, etc.

2) Critical to note in Black or Mediterranean patients to ask abou sickle cell trait and disease

Why is sickle cell a concern?



- Only since 2006, have all states required and provided universal newborn screening for SCD
- If IOP elevated with hyphema, order:
- Sickle cell prep: Screener for sick cell
- Hemoglobin electrophoresis: Diagnostic in determining sickle cell trait or disease
- May take time to get results so proceed keeping possibility in mind
 - Approximately 10% carry the HbS gene



I ordered sickle screening Did come back negative Topical Therapy Cycloplegic Atropine qd Steroid q 2hs initially Glaucoma Drops Which ones would you not choose?

Glaucoma Meds

- Best choice is beta blocker and alpha agonists
 - Avoid prostaglandin as it can increase inflammation
- Avoid oral and topical carbonic anhydrase inhibitors in patients with sickle cell trait or disease
- Can increase sickling of erythrocytes
 Alters aqueous pH> acidosis > promotes sickling
- Methazolamide may be a better choice in this situation (Neptazane 50 mg PO q8h).

I started combo brimonidine/timolol b.i.d.



Treatment

- Supportive treatment
 - Eye shield at all times (during the day and at night)
 - Strict bed rest has not been shown to be beneficial in comparison to mild activity
- Head elevation (up to 30°) helps level the blood inferiorly and keeps the central cornea and pupil aperture unobstructed
- Aspirin/NSAIDs should be avoided to prevent rebleeding



Going Home Instructions

- Atropine q.d.
 Steroid q2hrs.
- Brimonidine/timolol b.i.d.
- Eye Shield
- Bed Rest
- Sleep Propped Up
- RD Warnings Given
- Education on future risk of Glaucoma if angle recession present
- Gonio in a few weeks
- Lab Orders for Sickle Prep Screen Stat





Weeks to come

- Continue to monitor every few days until hyphema resolves
- Adjust meds as condition improves
 Taper Durezol- rebound iritis
- Re-examine fundus as soon as you get visibility of retina
- Gonio at 4-6 weeks to look for angle recession
 - If present, get baseline OCT and VF
 Monitor every 6 months for change over time
 Significant education on angle recession critical



- 73 yr old white female reports on a Saturday AM for a complete eye exam because the vision in right eye has been blurry since she had covid 4 months ago
 Complains of a dull ache behind the eye possibly
- 2x/week, does not last very long
- Pt denies new floaters but notes they've been having some flashes like looking at stars
- Medical History:
- Thyroid Disease, HTN, HOH, Arthriti
- Systemic Meds:
 - Levothyroxine, Losartan

VA OD: Dcc20/50-1. Pinhole20/30-2. OS: Dcc20/30+2

- Present Glasses: OD +2.25 +1.00 006 +3.00 OS +2.00 +1.00 009 +3.00
- Pupils: OD: Minimal reaction 5mm fixed OS: 2+ reactivity 3mm Round
- IOP: App OD: 61,62 OS: 19,21

OD Cornea: 1+ ABMD A/C: Shallow and Quiet Iris Normal Appearing Lens 1-2+ NS.

OS Cornea: tr ABMD A/C: Shallow and Quiet Iris: Normal Appearing Lens: 1-2+ NS

Gonioscopy: OD SL 360 no structures seen with evidence PAS on indentation OS TM inferior with SL nasal, temporal, and superior





Diagnosis

- Chronic Angle Closure Glaucoma Indeterminant OD
- Angle Closure OS



What do you do next? Panic? Refer for LPI? Order VF/OCT? Remember this has been going on for awhile- months even First try to pharmacologically break the attack and lower IOP Helpsmake the PI easier to perform LPI does not have to happen stat right then- can wait until Monday. You do need to protect the other eye as well

THEAST OH

- Start beta blocker, alpha agonist, pilocarpine and topical CAI spacing drops about 10 mins apart
- Can give prostaglandin but may not be as effective over IOP 55mmHG
 Also add topical Prednisone for inflammation
- Give two 250mg tablets of oral Acetazolomide in office
- Check IOP in 40 minutes
- Send patient home with all topical drops plus 500mg oral CAI
 Put patient on 1% Pilo gid for OS tp prevent AAC attack until LPI parformed
- Schedule patient for Monday AM LPI OU unless you are in a state where you can perform the LPI right then

LPI was successfully performed Monday AM OU- now what?

- Measure IOP next day- patient was still on combo topical beta blocker and alpha agonist plus prostaglandin
- IOP was 11 OD and 13 OS next day
 Stage the glaucoma and evaluate damage and need for further treatment

Recheck gonio and LPI patency at 3-4 weeks







• OD: Severe Angle Closure Glaucoma OS: Angle Closure

Next Steps?

With amount of damage OD IOP goal set to < 14mmHg. OS goal <22mmHg
Patient to stay on combo brimonidine/timolol bid OD
Can trial stopping prostaglandin OD
No topical meds needed OS
Will monitor patient every 4-6 months
What about clear lens extraction?

